HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Single administration of a novel γ-secretase modulator ameliorates cognitive dysfunction in aged C57BL/6J mice.

Abstract
Mutations in presenilin 1 (PS1) and presenilin 2 (PS2) are known to cause early onset of Alzheimer's disease (AD). These proteins comprise the catalytic domain of γ-secretase, which catalyzes the cleavage of β-amyloid (Aβ) from amyloid precursor protein (APP). In recent reports, PS1 and PS2 were linked to the modulation of intracellular calcium ion (Ca(2+)) dynamics, a key regulator of synaptic function. Ca(2+) dysregulation and synaptic dysfunction are leading hypothesis of cognitive dysfunctions during aging and AD progression. Accordingly, manipulations of presenilins by small molecules may have therapeutic potential for the treatment of cognitive dysfunction. In an accompanying report, we showed that chronic treatment with compound-1, a novel γ-secretase modulator (GSM), reduced Aβ production and ameliorated cognitive dysfunction in Tg2576 APP transgenic mice. Accordingly, in the present study we showed that single oral administration of compound-1 at 1 and 3mg/kg ameliorated cognitive dysfunction in aged non-transgenic mice. Moreover, compound-1 enhanced synaptic plasticity in hippocampal slices from aged C57BL/6J mice and increased messenger RNA (mRNA) expression of the immediate early gene c-fos, which has been shown to be related to synaptic plasticity in vivo. Finally, compound-1 modulated Ca(2+) signals through PS1 in mouse embryonic fibroblast cells. Taken together, compound-1 ameliorates both Aβ pathology and age-related cognitive dysfunctions. Hence, compound-1 may have potential as an early intervention for the cognitive declines that are commonly diagnosed in aged subjects, such as mild cognitive impairment (MCI) and prodromal AD.
AuthorsTatsuya Hayama, Koji Murakami, Tomomichi Watanabe, Ryota Maeda, Makoto Kamata, Shinichi Kondo
JournalBrain research (Brain Res) Vol. 1633 Pg. 52-61 (Feb 15 2016) ISSN: 1872-6240 [Electronic] Netherlands
PMID26707406 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Elsevier B.V. All rights reserved.
Chemical References
  • 2-(3-(3-methoxy-4-(2-methyl-1,3-oxazol-5-yl)phenyl) -8-(3,4,5-trifluorophenoxy)-5,6,7,8-tetrahydro(1,2,4)triazolo(4,3-a)pyridin-8-yl)propan-2-ol
  • Neuroprotective Agents
  • Pyridines
  • Triazoles
  • Amyloid Precursor Protein Secretases
Topics
  • Alzheimer Disease
  • Amyloid Precursor Protein Secretases (metabolism)
  • Animals
  • Cognition (drug effects)
  • Cognition Disorders (etiology)
  • Disease Models, Animal
  • Hippocampus (drug effects)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Neuronal Plasticity (drug effects)
  • Neuroprotective Agents (pharmacology)
  • Patch-Clamp Techniques
  • Pyridines (pharmacology)
  • Triazoles (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: